Melanoma Clinical Trials in Cleveland

Showing 141-160 of 306 trials

COMPLETED< 1 mile

Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting

NCT05079113

To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.

Stage III MelanomaStage IV Cutaneous Melanoma

Case Comprehensive Cancer Center73 participantsStarted Oct 2019

Cleveland, Ohio, United States

COMPLETEDPhase 1/2< 1 mile

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

NCT03123783

This study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with non-small cell lung cancer or metastatic melanoma. The Phase 1 portion is intended to establish the maximum tolerated dose and the recommended phase 2 dose of APX005M when administered in combination with nivolumab. The Phase 2 portion of the study will evaluate safety and efficacy of the combination.

CancerNon Small Cell Lung Cancer MetastaticMetastatic Melanoma+2 more

Apexigen America, Inc.140 participantsStarted Jul 2017

Tucson, Arizona, United States • Duarte, California, United States • New Haven, Connecticut, United States +20 more locations

Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Melanoma Trials in Other Cities

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Study in Subjects With Small Primary Choroidal Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

Other Conditions in Cleveland